• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia.印度尼西亚巴厘岛桑格拉总医院三阴性乳腺癌患者肿瘤浸润淋巴细胞及程序性细胞死亡蛋白1表达与远处转移发生率的相关性
Case Rep Oncol. 2021 Mar 8;14(1):347-351. doi: 10.1159/000514272. eCollection 2021 Jan-Apr.
2
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.局部晚期三阴性乳腺癌中肿瘤浸润淋巴细胞、程序性死亡配体-1 表达与中性粒细胞-淋巴细胞比值的预后作用及临床相关性。
Cancer Res Treat. 2019 Apr;51(2):649-663. doi: 10.4143/crt.2018.270. Epub 2018 Jul 31.
3
Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.三阴性乳腺癌中与程序性死亡配体1表达相关的肿瘤浸润淋巴细胞的多光谱定量免疫组织化学分析
Breast Cancer. 2020 Jul;27(4):519-526. doi: 10.1007/s12282-020-01110-2. Epub 2020 May 23.
4
Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.三阴性乳腺癌中 TIL 和 PD-L1 的临床病理和预后价值。
Pathol Res Pract. 2023 Oct;250:154828. doi: 10.1016/j.prp.2023.154828. Epub 2023 Sep 22.
5
Prognosis-related novel immunostaining pattern for programmed cell death ligand 1 and prognostic value of tumour-infiltrating lymphocytes in triple-negative breast cancer.三阴性乳腺癌中程序性细胞死亡配体 1 的预后相关新型免疫组化模式及肿瘤浸润淋巴细胞的预后价值。
Pol J Pathol. 2023;74(2):65-74. doi: 10.5114/pjp.2023.129014.
6
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌(TNBC)中肿瘤浸润淋巴细胞(TILs)和程序性死亡配体 1(PD-L1)表达的状态所阐明。
Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.
7
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.肿瘤浸润淋巴细胞(TIL)和程序性死亡配体1(PD-L1)表达在三阴性乳腺癌(TNBC)中的预后作用及临床意义:一项系统评价和荟萃分析研究
Diagnostics (Basel). 2020 Sep 17;10(9):704. doi: 10.3390/diagnostics10090704.
8
Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer.三阴性乳腺癌核心针活检与手术标本中程序性死亡配体 1 状态的比较。
Yonsei Med J. 2023 Aug;64(8):518-525. doi: 10.3349/ymj.2023.0090.
9
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.程序性死亡配体1(PD-L1)肿瘤表达与三阴性乳腺癌患者的较好预后及糖尿病疾病相关。
Int J Mol Sci. 2017 Feb 21;18(2):459. doi: 10.3390/ijms18020459.
10
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.程序性死亡配体-1 与肿瘤浸润淋巴细胞相关,并与膀胱癌的生存状况较差相关。
Cancer Sci. 2019 Feb;110(2):489-498. doi: 10.1111/cas.13887. Epub 2018 Dec 12.

本文引用的文献

1
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.三阴性乳腺癌患者中PD-L1表达与临床病理参数的相关性
Eur J Breast Health. 2019 Oct 1;15(4):235-241. doi: 10.5152/ejbh.2019.4912. eCollection 2019 Oct.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
The Epithelial-to-Mesenchymal Transition in Cancer.癌症中的上皮-间质转化
Cancers (Basel). 2018 Feb 16;10(2):52. doi: 10.3390/cancers10020052.
4
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.三阴性乳腺癌有多少种疾病:免疫微环境的主导作用
ESMO Open. 2017 Sep 14;2(4):e000208. doi: 10.1136/esmoopen-2017-000208. eCollection 2017.
5
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.程序性死亡受体配体1(PD-L1)表达与肿瘤浸润淋巴细胞减少相结合,与三阴性乳腺癌的不良预后相关。
Oncotarget. 2017 Feb 28;8(9):15584-15592. doi: 10.18632/oncotarget.14698.
6
Immune targeting in breast cancer.乳腺癌中的免疫靶向治疗
Oncology (Williston Park). 2015 May;29(5):375-85.
7
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.肿瘤浸润淋巴细胞在三阴性乳腺癌中具有预后价值,并可预测早期乳腺癌曲妥珠单抗获益:FinHER 试验结果。
Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.
8
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.PD-L1 表达在肾透明细胞癌中的表达:肾切除术和转移部位的分析。
J Cancer. 2014 Jan 24;5(3):166-72. doi: 10.7150/jca.8167. eCollection 2014.
9
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.在黑色素瘤肿瘤微环境中,PD-L1、IDO 和 T(regs)的上调是由 CD8(+) T 细胞驱动的。
Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: 10.1126/scitranslmed.3006504.
10
Hallmarks of cancer: the next generation.癌症的特征:下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.

印度尼西亚巴厘岛桑格拉总医院三阴性乳腺癌患者肿瘤浸润淋巴细胞及程序性细胞死亡蛋白1表达与远处转移发生率的相关性

The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia.

作者信息

Sudarsa I Wayan, Gunawan I Putu Ari, Manuaba Ida Bagus Tjakra Wibawa

机构信息

Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Udayana University, Sanglah General Hospital, Denpasar, Indonesia.

出版信息

Case Rep Oncol. 2021 Mar 8;14(1):347-351. doi: 10.1159/000514272. eCollection 2021 Jan-Apr.

DOI:10.1159/000514272
PMID:33776728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7983624/
Abstract

The triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with a high rate of distant metastasis. The tumor immunity microenvironment plays an important role, including tumor-infiltrating lymphocytes (TIL) and PD-1 (programmed cell death 1)/PD-L1 (programmed cell death-ligand 1), in promoting TNBC aggressiveness. This study aimed to determine the association of TIL and PD-L1 expression with the incidence of distant metastasis in TNBC. This study is a cross-sectional study involving TNBC subjects at Sanglah General Hospital, Denpasar, conducted in 2019. The parameters analyzed were the expression of TIL, PD-L1, and the incidence of distant metastasis. The expression of TIL was analyzed histopathologically while PD-L1 was measured with Ventana PD-L1 kit test. Subject characteristics were obtained from medical records. Data were collected and analyzed by SPSS 22.0. As many as 31 subjects with TNBC were included in this study, with 51.6% subjects with distant metastasis. The majority of subjects with distant metastasis had low TIL and low tumoral PD-L1 but high PD-L1 stromal in TIL. From statistical analysis, only PD-L1 stromal in TIL expression was associated significantly with distant metastasis ( = 0.043). In conclusion, there was a significant association between PD-L1 stromal in TIL and the incidence of distant metastasis in TNBC.

摘要

三阴性乳腺癌(TNBC)是最具侵袭性的乳腺癌亚型,远处转移率高。肿瘤免疫微环境在促进TNBC侵袭性方面发挥着重要作用,包括肿瘤浸润淋巴细胞(TIL)和程序性死亡蛋白1(PD-1)/程序性死亡配体1(PD-L1)。本研究旨在确定TIL和PD-L1表达与TNBC远处转移发生率之间的关联。本研究为横断面研究,于2019年在登巴萨桑格拉总医院对TNBC患者进行。分析的参数包括TIL、PD-L1的表达以及远处转移的发生率。TIL的表达通过组织病理学分析,而PD-L1则用Ventana PD-L1试剂盒检测。患者特征从病历中获取。数据通过SPSS 22.0收集和分析。本研究共纳入31例TNBC患者,其中51.6%发生远处转移。大多数发生远处转移的患者TIL水平低、肿瘤PD-L1水平低,但TIL中的基质PD-L1水平高。经统计学分析,仅TIL中基质PD-L1的表达与远处转移显著相关(P = 0.043)。总之,TIL中的基质PD-L1与TNBC远处转移发生率之间存在显著关联。